ClinicalTrials.gg
RecruitingNCT06326502Updated Mar 27, 2024

A Safety and Efficacy Study of Multiple Tyrosine Kinase Inhibitor Drug (ETN101) in Advanced Hepatocellular Carcinoma

A Phase 1 interventional study of ETN101 in Hepatocellular Carcinoma, Advanced Hepatocellular Carcinoma and Liver Cancer, sponsored by Etnova Therapeutics Corp.. Recruiting at 2 sites in Korea, Republic of. Open to participants aged 19 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-03-27.

Sponsored by Etnova Therapeutics Corp. · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2024; still recruiting 2 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
19 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 298 studies in Carcinoma, Hepatocellular with a site in Korea, Republic of — 50 open to participants now, 74 under way, 8 of them phase 3. Carcinoma, Hepatocellular · Korea, Republic of.

Planned enrollment
169th of 255
50 · median 87
Started
2024
with 10 others
Phase 1
26 of 298
9 open now
Primary completion
2027-03
later than 33 of 73 live
Registered
260th of 298
by date

Among the 298 studies in Carcinoma, Hepatocellular with a site in Korea, Republic of, this one is the 169th largest by planned enrollment of the 255 interventional ones that give a count, is one of 11 that started in 2024, is one of 26 in phase 1, reaches primary completion later than 33 of the 73 other live ones, and was the 260th registered.

Carcinoma, Hepatocellular

3,656 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,068 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

50 of the 298 studies in Carcinoma, Hepatocellular with a site in Korea, Republic of are open now. Recruiting first, the newest first:

45 more — sign in →

All 50 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 743 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 253 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 19 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 298 studies in Carcinoma, Hepatocellular with a site in Korea, Republic of, or all of them as a file.
02

Study summary

ETN101 is a multiple tyrosine kinase inhibitor (mTKI) targeting fms-like tyrosine kinase 3 (FLT3), receptor tyrosine kinase (KIT), vascular endothelial growth factor receptor 2 (VEGFR2), and platelet-derived growth factor receptor beta. Both in vitro and in vivo studies showed that ETN101 treatment/administration inhibited cancer cell survival and proliferation. In animal models, ETN101 had antitumor activity when administered to animals that did not respond to conventional targeted anticancer agents.

Read the detailed description

The study drug, ETN101, is an mTKI targeting FLT3, VEGFR2, PDGFR-beta, and KIT. Based on its preclinical study results, the study drug was anticipated to have a potent anticancer effect by blocking the signaling pathway of receptor tyrosine kinases. In animal models with subcutaneously transplanted liver cancer cells (HepG2), complete remission (CR) or partial remission (PR) were observed in animals treated with ETN101 at doses of 20\~82 mg/kg. In addition, ETN101 82 mg/kg induced CR and PR in animals that had not responded to HCC therapies, sorafenib and lenvatinib. ETN101 10 mg/kg was found to have antitumor efficacy as demonstrated by approximately 30% suppression of tumor growth in comparison with a negative control.

Overall, ETN101 is anticipated to have anticancer activity as a targeted therapy in the treatment of advanced HCC that did not respond to prior therapy or that recurred subsequently, and therefore, is expected to offer a new treatment opportunity for patients with advanced hepatocellular carcinoma (HCC) for whom therapeutic options are limited.

Therefore, this study aims to evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of ETN101, and to determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of ETN101 in patients with HCC who previously had second- or further-line anticancer treatment.

03

Conditions studied

  • Hepatocellular Carcinoma
  • Advanced Hepatocellular Carcinoma
  • Liver Cancer

Keywords

  • HCC
04

Who can participate

Ages eligible
19 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male and female adult at the age of ≥ 19 years old
  2. Patients with radiologically or histologically, and/or confirmed advanced HCC who have confirmed disease progression on standard therapies known to have clinical benefit or for whom there is no currently available standard therapy due to intolerance or incompatibility.
  3. Subject with Barcelona Clinic Liver Cancer (BCLC) stage B or C; Subject with Stage B must have had progressive disease (PD) after radical resection, liver transplant, embolization, or cauterization or must be ineligible for such treatment.
  4. Subject with score A (5-6)
  5. Subject who has at least one measurable target lesion based on modified () which was not previously treated with local therapy. A lesion previously treated with local therapy may be selected as a target lesion if an increase of ≥20% in size is confirmed after treatment.
  6. Subject with (ECOG) status performance 0-1.
  7. Subject with ≥ 12 weeks of
  8. Subject who meets the following criteria for laboratory tests (Subject must not have been treated with granulocyte colony-stimulating factor (G-CSF) or blood transfusions within 14 days prior to the laboratory tests.):

    • Hematology

      • (ANC) ≥1,500/mm3
      • count ≥60,000/mm3
      • (Hb) ≥8.5 g/dL
    • Kidney function: Serum creatinine ≤1.5 × (ULN)
    • Liver function

      • (AST) and alanine aminotransferase(ALT) ≤5 × ULN
      • Total ≤2.0 × ULN (≤3.0 × ULN for Gilbert's disease)
    • Blood coagulation function: (PT/INR) and activated partial thromboplastin time (aPTT) ≤1.5 × ULN
  9. Subject who voluntarily agrees to participate in the study and signs the form (ICF) after being fully informed of the study

Exclusion criteria

Exclusion Criteria:

  1. Individual with severe drug sensitivity or sensitivity reactions to IP and any of its components or drugs in similar classes
  2. Individual with a confirmed disease which makes oral drug administration difficult or which affects the absorption of orally administered drugs (celiac disease, Crohn's disease, or enterectomy affecting absorption, etc.)
  3. Individual with any of the following past medical history or surgical/procedure history:

    1. History of other primary cancer within 3 years from screening (However, individuals who had skin basal cell carcinoma/squamous cell carcinoma, local prostate cancer, papillary thyroid cancer, or cervical intraepithelial neoplasia within 3 years may participate in the study if it is confirmed by the investigator to have been cured following successful treatment.)
    2. Hepatic radiation, chemoembolization, or radiofrequency ablation within 4 weeks prior to IP administration
    3. Major surgery within 4 weeks or minor surgery within 2 weeks prior to IP administration
    4. arrhythmia, acute myocardial infarction, unstable angina pectoris, or (NYHA) Ⅲ or Ⅳ heart failure within 6 months prior to IP administration
    5. Severe cerebrovascular disease within 6 months prior to IP administration
    6. Pulmonary thrombosis, deep vein thrombosis, or bronchial asthma or obstructive pulmonary disease that is considered ineligible for study participation, or other life-threatening severe pulmonary disease (e.g., acute respiratory distress syndrome, lung failure) within 6 months prior to IP administration
  4. Individual with any of the following diseases:

    1. Clinically significantly symptomatic or uncontrolled central nervous system or (However, individuals who have been stable for ≥ 4 weeks based on repeated imaging and clinical observations, as confirmed by clinical and imaging tests during the screening period, may participate in the study.)
    2. Clinically significant (ECG) abnormalities based on the judgment of the investigator
    3. Uncontrolled hypertension (systolic blood pressure [BP] >140 mmHg or diastolic BP >90 mmHg)
    4. Grade ≥ 3 active infectious disease requiring treatment. However, individuals with and may be enrolled if replication activity is undetectable (HBV DNA below the limit of detection) and antiviral treatment against hepatitis C is not required, respectively.
    5. Active disease requiring systemic treatment
    6. Known (HIV) infection
    7. Symptomatic ascites or pleural effusion (However, patients who are treated and clinically stabilized may be enrolled.)
    8. Grade ≥ 3(≥3.5 g/24 h) proteinuria
    9. Any disease that may affect the interpretation of study results based on the judgment of the investigator
  5. Individuals who have any of the following history of medication or treatment:

    1. Anticancer therapy [chemotherapy, hormone therapy, targeted therapy, or radiotherapy, etc.] within 4 weeks prior to IP administration
    2. within 4 weeks prior to IP administration
    3. Strong CYP1A2 inhibitors within 2 weeks prior to IP administration
    4. Prior allogeneic bone marrow or solid organ transplantation
  6. Pregnant or lactating woman, or man or woman of who is unwilling to practice abstinence or to use adequate methods of * from after study enrollment to at least 6 months (in female subjects) or 3 months (in male subjects) after the last dose of IP

    * Adequate methods of contraception

    • Hormonal contraception (subdermal contraceptive implants, injections, oral contraceptives)
    • Insertion of intrauterine device or intrauterine system
    • Subject's or spouse (partner)'s surgical sterilization (vasectomy, tubal ligation, etc.)
  7. Individual with prior chemotherapy related toxicity not recovered to Grade ≤ 1 or baseline level (with the exception of alopecia)
  8. Individual who is unable to undergo contrast-enhanced CT or MRI
  9. Individual who was treated with another IP or device within 4 weeks prior to IP administration in the present study
  10. Patient who is ineligible or unable to participate in the study for other reasons based on the judgment of the investigator
Terms in these criteria, in plain language(26)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

iRECIST and mRECIST

Versions of RECIST adapted to particular cases. iRECIST is for immunotherapy, where a tumor can look bigger for a while before it shrinks, so growth has to be confirmed on a later scan. mRECIST usually means the version for liver cancer (hepatocellular carcinoma), which measures only the part of a tumor that still has a blood supply.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    ETN101

    ETN101

    Drug: ETN101

Interventions

  • DrugETN101

    Oral administration

06

What researchers measure

Primary outcomes

  1. Dose-limiting Toxicity (DLT)

    DLT will be monitored during Cycle 1 (3 weeks) starting from the start date of intraperitoneal (IP) dosing

    Time frame: Up to 3 weeks after start of injection

07

Study locations

2 of 2 sites recruiting
08

References and documents

Publications

  • Park HJ, Choi G, Ha S, Kim Y, Choi MJ, Kim M, Islam MK, Chang Y, Kwon TJ, Kim D, Jang E, Kim TH, Chang SJ, Kim YH. MBP-11901 Inhibits Tumor Growth of Hepatocellular Carcinoma through Multitargeted Inhibition of Receptor Tyrosine Kinases. Cancers (Basel). 2022 Apr 14;14(8):1994. doi: 10.3390/cancers14081994. PubMed 35454900 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2024 (actual). Primary completion is estimated for Mar 2027, 37 months after the start.

Of 103 industry-sponsored phase 1 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 65. This study's planned 37 months is below that.

Counting every sponsor, half of 250 studies reached it within 49 months; a quarter within 32 and three quarters within 77.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 17, 2024
First posted
Mar 22, 2024
StartActual
Feb 7, 2024
Primary completionEst.
Mar 7, 2027
CompletionEst.
Jun 7, 2027
Last update
Mar 27, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 27, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06326502
Lead sponsor
Etnova Therapeutics Corp.
Responsible party
Sponsor
First posted
Mar 22, 2024
Start date
Feb 7, 2024
Primary completion
Mar 7, 2027 (estimated)
Completion
Jun 7, 2027 (estimated)
Last update
Mar 27, 2024

Study contacts

HyeJin Yang, Ph.D
Contact
hjyang@etnova.co.kr
82-10-2573-1857
Yeonhee Kim, Ph.D
study director · Etnova Therapeutics

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion